REDWOOD CITY, Calif., Feb. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that David Anton, Ph.D. has been promoted to Chief Technology Officer and Senior Vice President, Process Development and Manufacturing, a new position. He will continue to report to Alan Shaw, Ph.D., President and Chief Executive Officer.
Dr. Anton joined Codexis in 2008 after a 25-year career with DuPont. He served as Vice President, Research and Development for Codexis Bioindustrials from 2008-09, and Senior Vice President, Research and Development from 2009-11.
"Under Dave Anton's leadership, Codexis R&D has grown to an organization that today is developing commercial products and processes in four global markets – biofuels, pharmaceuticals, carbon capture and biobased chemicals," Dr. Shaw said. "His nearly three decades of experience in technology development and commercialization – including commercial scale-up and manufacturing - will be important as we continue our transition to a product company."
Dr. Anton joined DuPont in 1983, and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.
He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He was a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee from 2006 to 2008.
Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture with Alstom. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. For more information, see www.codexis.com.
This press release contains forward-looking statements relating to the potential expansion of our business. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 10, 2011, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
SOURCE Codexis, Inc.